Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial

BACKGROUND: Patients with extensive-stage small-cell lung cancer (ES-SCLC) have a particularly poor prognosis. And the treatment options for patients with relapsed or refractory ES-SCLC are limited. Thus, we conducted an open-label, multicenter, single-arm phase II clinical trial to assess the effic...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Zhen, Zhou, Hanqiong, Wang, Junsheng, Li, Ding, Zhang, Xudong, Wang, Pengyuan, Ma, Tianjiang, Zhang, Yueqiang, Tian, Chuntao, Chen, Yunfang, Zou, Minglei, Han, Yu, Xu, Cong, Ma, Shuxiang, Wang, Lili, Wu, Xuan, Chen, Gongbin, Wang, Qiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947412/
https://www.ncbi.nlm.nih.gov/pubmed/33718030
http://dx.doi.org/10.21037/tlcr-20-1235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947412/
https://www.ncbi.nlm.nih.gov/pubmed/33718030
http://dx.doi.org/10.21037/tlcr-20-1235

Ejemplares similares